Purpose: Previous investigations have explored molecular differences between proliferative vitreoretinopathy and primary retinal detachment. An exploration of a greater number of molecules might provide novel insight into the biology of this disorder and identify potential therapeutic targets.
Methods: Vitreous specimens were obtained from patients with epiretinal membranes or macular puckers (n = 15), patients with a primary retinal detachment without proliferative vitreoretinopathy (n = 15), and patients with retinal detachments and proliferative vitreoretinopathy (n = 15). A multiplex assay was performed to calculate the concentrations of 48 different cytokines and chemokines, and statistical analyses were performed to identify differences between the groups.
Results: Of the 48 molecules that were studied, we identified 10 that were statistically significantly different in cases of proliferative vitreoretinopathy, including interleukins 4, 5, 6, and 15; granulocyte–macrophage colony-stimulating factors; stem cell factor; stem cell growth factor; macrophage inflammatory protein 1α; and interferon γ–induced protein 10.
Conclusion: Proliferative vitreoretinopathy represents a highly ordered molecular process that involves discrete changes in the concentrations of specific cytokines and chemokines. These molecules may represent novel therapeutic targets.
In this study, we have expanded the number of molecules that have been studied in proliferative vitreoretinopathy and have identified novel differences between this disorder, vitreous in the absence of retinal detachment, and primary retinal detachment.
*Ophthalmic Plastic Surgery, Lions Eye Institute, Albany Medical College, Slingerlands, New York
‡Center for Immunology and Microbial Disease, Albany Medical College, Albany, New York.
Reprint requests: Edward J. Wladis, MD, FACS, Ophthalmic Plastic Surgery, Lions Eye Institute, Albany Medical College, 1220 New Scotland Road, Suite 302, Slingerlands, NY 12159; e-mail: email@example.com
Supported by a research grant from the Lions Eye Foundation (Albany, NY). The sponsor had no role in the development of this project.
The authors declare no conflict of interest.